Miglustat: Substrate reduction therapy for glycosphingolipid storage disorders

Therapy

Volumn 2, Issue 4, 2005, Pages 569-576

  Lachmann, Robin H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Gaucher disease; Glycosphingolipid; Lysosomal storage disorders; Miglustat; Substrate reduction therapy

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALGLUCERASE; GLYCOSPHINGOLIPID; IMIGLUCERASE; MIGLUSTAT;

ALLELE; ARTICLE; BODY WEIGHT DISORDER; CATARACT; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; FABRY DISEASE; GASTROINTESTINAL TOXICITY; GAUCHER DISEASE; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MALE INFERTILITY; NEUROLOGIC DISEASE; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PREVALENCE; TREMOR; WEIGHT REDUCTION;

EID: 22544468503     PISSN: 14750708     EISSN: None     Source Type: Journal    
DOI: 10.1586/14750708.2.4.569     Document Type: Article

References (32)

1. Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nature Rev. Mol. Cell. Biol. 5(7), 554-565 (2004).
2. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Biol. Chem. 264(21), 12115-12118 (1989).
3. Brady RO, Schiffmann R. Enzyme-replacement therapy for metabolic storage disorders. Lancet Neurol. 3(12), 752-726 (2004).
4. Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 13(2), 153-157 (1996).
5. Platt FM Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269(11), 8362-8365 (1994).
6. Beutler GA, Grabowski E. Gaucher disease. In: The Metabolic and Molecular Bases of Inherited Disease Scriver CR (Ed.). McGraw-Hill, NY, USA 3635-3668 (2001).
7. Beutler E, Gelbart T. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am. J. Hum. Genet. 52(1), 85-88 (1993).
8. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J. Am. Med. Assoc. 281(3), 249-254 (1999).
9. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 38(11), 769-775 (2001).
10. Wilcox WR, Banikazemi M, Guffon N. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 75(1), 65-74 (2004).
11. Beck M, Ricci R, Widmer U et al. Fabry disease: overall effects of agalsidase-α treatment. Eur. J. Clin. Invest. 34(12), 838-844 (2004).
12. Walkley SU. Neurobiology and cellular pathogenesis of glycolipid storage diseases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 358(1433), 893-904 (2003).
13. Overkleeft HS, Renkema GH, Neele J et al. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J. Biol. Chem. 273(41), 26522-26527 (1998).
14. Andersson U, Smith D, Jeyakumar M et al. Improved outcome of N-buodeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol. Dis. 16(3), 506-515 (2004).
15. Abe A, Wild SR, Lee WL, Shayman JA et al. Agents for the treatment of glycosphingolipid storage disorders. Curr. Drug. Metab. 2(3), 331-338 (2001).
16. Butters TD, Mellor HR, Narita K, Dwek RA, Platt FM. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 358(1433), 927-945 (2003).
17. Fischl MA, Resnick L, Coombs R et al. The safety and efficacy of combination N-butyldeoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J. Acq. Immun. Def. Synd. 7(2),139-147 (1994).
18. Platt FM, Reinkensmeier G, Dwek RA, Butters TD. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J. Biol. Chem. 272(31), 19365-19372 (1997).
19. Platt FM, Neises GR, Reinkensmeier G et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276(5311), 428-431 (1997).
20. Jeyakumar M, Butters TD, Cortina-Borja M et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 96(11), 6388-6393 (1999).
21. Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J. Neuropathol. Exp. Neurol. 60(1), 49-64 (2001).
22. Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr. Biol. 11(16), 1283-1287 (2001).
23. van der Spoel AC, Jeyakumar M, Butters TD et al. Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc. Natl Acad. Sci. USA99(26), 17173-17178 (2002).
24. Cox T, Lachmann R, Hollak C et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214), 1481-1485 (2000).
25. Jeyakumar M, Thomas R, Elliot-Smith E et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126(Pt 4), 974-987 (2003).
26. Lachmann RH, te Vruchte D, Lloyd-Evans E et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol. Dis. 16(3), 654-658 (2004).
27. Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J. Clin. Invest. 93(3), 1288-1292 (1994).
28. Elstein D, Hollak C, Aerts JM et al. Sustained therapeutic effects of oral miglustat (Zavesca N-butyldeoxynojirimycin OGT 918) in Type I Gaucher disease. J. Inherit. Metab. Dis. 27(6), 757-766 (2004).
29. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Quantification of skeletal involvement in adults with Type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am. Roentgenol. J. 179(4), 961-965 (2002).
30. Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for Type I Gaucher disease. Blood Cells Mol. Dis. 28(2), 127-133 (2002).
31. Cox TM, Aerts JM, Andria G et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of Type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26(6), 513-526 (2003).
32. Lachmann RH, and FM. Platt Substrate reduction therapy for glycosphingolipid storage disorders. Exp. Opin. Invest. Drugs 10(3), 455-466 (2001).